AT7687

Asset

Blocks the glucose-dependent insulinotropic polypeptide receptor to treat obesity.

Stage
Phase 1
Modality
Peptide
Target
GIPR
1
Indication
0
Trials
1
Developer

Indications

1
  • Obesity

    Phase 1, doi.org, 7 Jun 2026

In the full profile

  • Targets and what it contains1
  • Owner and partners1
  • Evidence for its targets2
  • Competitors12
  • Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets